Search

Your search keyword '"O’Reilly, Richard J."' showing total 189 results
Start Over Author "O’Reilly, Richard J." Publication Year Range Last 3 years
189 results on '"O’Reilly, Richard J."'

3. Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell–depleted hematopoietic cell transplantation in pediatric and young adult patients

Author

Lakkaraja, Madhavi, Mauguen, Audrey, Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Harris, Andrew C., Kernan, Nancy A., Klein, Elizabeth, Kung, Andrew L., Oved, Joseph, Prockop, Susan, Scaradavou, Andromachi, Spitzer, Barbara, O'Reilly, Richard J., and Boelens, Jaap Jan

Published
2024
Full Text
View/download PDF

4. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Author

Mahadeo, Kris Michael, Baiocchi, Robert, Beitinjaneh, Amer, Chaganti, Sridhar, Choquet, Sylvain, Dierickx, Daan, Dinavahi, Rajani, Duan, Xinyuan, Gamelin, Laurence, Ghobadi, Armin, Guzman-Becerra, Norma, Joshi, Manher, Mehta, Aditi, Navarro, Willis H, Nikiforow, Sarah, O'Reilly, Richard J, Reshef, Ran, Ruiz, Fiona, Spindler, Tassja, and Prockop, Susan

Published
2024
Full Text
View/download PDF

5. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study

Author

Eissa, Hesham, Thakar, Monica S., Shah, Ami J., Logan, Brent R., Griffith, Linda M., Dong, Huaying, Parrott, Roberta E., O’Reilly, Richard J., Dara, Jasmeen, Kapoor, Neena, Forbes Satter, Lisa, Chandra, Sharat, Kapadia, Malika, Chandrakasan, Shanmuganathan, Knutsen, Alan, Jyonouchi, Soma C., Molinari, Lyndsay, Rayes, Ahmad, Ebens, Christen L., Teira, Pierre, Dávila Saldaña, Blachy J., Burroughs, Lauri M., Chaudhury, Sonali, Chellapandian, Deepak, Gillio, Alfred P., Goldman, Fredrick, Malech, Harry L., DeSantes, Kenneth, Cuvelier, Geoff D.E., Rozmus, Jacob, Quinones, Ralph, Yu, Lolie C., Broglie, Larisa, Aquino, Victor, Shereck, Evan, Moore, Theodore B., Vander Lugt, Mark T., Mousallem, Talal I., Oved, Joeseph H., Dorsey, Morna, Abdel-Azim, Hisham, Martinez, Caridad, Bleesing, Jacob H., Prockop, Susan, Kohn, Donald B., Bednarski, Jeffrey J., Leiding, Jennifer, Marsh, Rebecca A., Torgerson, Troy, Notarangelo, Luigi D., Pai, Sung-Yun, Pulsipher, Michael A., Puck, Jennifer M., Dvorak, Christopher C., Haddad, Elie, Buckley, Rebecca H., Cowan, Morton J., and Heimall, Jennifer

Published
2024
Full Text
View/download PDF

6. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation

Author

Tamari, Roni, Scordo, Michael, Kunvarjee, Binni M., Proli, Anthony, Lin, Andrew, Flynn, Jessica, Cho, Christina, Devlin, Sean, Klein, Elizabeth, Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O’Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Gyurkocza, Boglarka, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2023
Full Text
View/download PDF

7. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium

Author

Thakar, Monica S, Logan, Brent R, Puck, Jennifer M, Dunn, Elizabeth A, Buckley, Rebecca H, Cowan, Morton J, O'Reilly, Richard J, Kapoor, Neena, Satter, Lisa Forbes, Pai, Sung-Yun, Heimall, Jennifer, Chandra, Sharat, Ebens, Christen L, Chellapandian, Deepak, Williams, Olatundun, Burroughs, Lauri M, Saldana, Blachy Davila, Rayes, Ahmad, Madden, Lisa M, Chandrakasan, Shanmuganathan, Bednarski, Jeffrey J, II, DeSantes, Kenneth B, Cuvelier, Geoffrey D E, Teira, Pierre, Gillio, Alfred P, Eissa, Hesham, Knutsen, Alan P, Goldman, Frederick D, Aquino, Victor M, Shereck, Evan B, Moore, Theodore B, Caywood, Emi H, Lugt, Mark T Vander, Rozmus, Jacob, Broglie, Larisa, Yu, Lolie C, Shah, Ami J, Andolina, Jeffrey R, Liu, Xuerong, Parrott, Roberta E, Dara, Jasmeen, Prockop, Susan, Martinez, Caridad A, Kapadia, Malika, Jyonouchi, Soma C, Sullivan, Kathleen E, Bleesing, Jack J, Chaudhury, Sonali, Petrovic, Aleksandra, Keller, Michael D, Quigg, Troy C, Parikh, Suhag, Shenoy, Shalini, Seroogy, Christine, Rubin, Tamar, Decaluwe, Hélène, Routes, John M, Torgerson, Troy R, Leiding, Jennifer W, Pulsipher, Michael A, Kohn, Donald B, Griffith, Linda M, Haddad, Elie, Dvorak, Christopher C, and Notarangelo, Luigi D

Published
2023
Full Text
View/download PDF

9. The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions

Author

Dvorak, Christopher C., Haddad, Elie, Heimall, Jennifer, Dunn, Elizabeth, Cowan, Morton J., Pai, Sung-Yun, Kapoor, Neena, Satter, Lisa Forbes, Buckley, Rebecca H., O’Reilly, Richard J., Chandra, Sharat, Bednarski, Jeffrey J., Williams, Olatundun, Rayes, Ahmad, Moore, Theodore B., Ebens, Christen L., Davila Saldana, Blachy J., Petrovic, Aleksandra, Chellapandian, Deepak, Cuvelier, Geoffrey D.E., Vander Lugt, Mark T., Caywood, Emi H., Chandrakasan, Shanmuganathan, Eissa, Hesham, Goldman, Frederick D., Shereck, Evan, Aquino, Victor M., Desantes, Kenneth B., Madden, Lisa M., Miller, Holly K., Yu, Lolie, Broglie, Larisa, Gillio, Alfred, Shah, Ami J., Knutsen, Alan P., Andolina, Jeffrey P., Joshi, Avni Y., Szabolcs, Paul, Kapadia, Malika, Martinez, Caridad A., Parrot, Roberta E., Sullivan, Kathleen E., Prockop, Susan E., Abraham, Roshini S., Thakar, Monica S., Leiding, Jennifer W., Kohn, Donald B., Pulsipher, Michael A., Griffith, Linda M., Notarangelo, Luigi D., and Puck, Jennifer M.

Published
2023
Full Text
View/download PDF

10. The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions

Author

Dvorak, Christopher C., Haddad, Elie, Heimall, Jennifer, Dunn, Elizabeth, Buckley, Rebecca H., Kohn, Donald B., Cowan, Morton J., Pai, Sung-Yun, Griffith, Linda M., Cuvelier, Geoffrey D.E., Eissa, Hesham, Shah, Ami J., O’Reilly, Richard J., Pulsipher, Michael A., Wright, Nicola A.M., Abraham, Roshini S., Satter, Lisa Forbes, Notarangelo, Luigi D., and Puck, Jennifer M.

Published
2023
Full Text
View/download PDF

11. Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients

Author

Kernan, Nancy A., Klein, Elizabeth, Mauguen, Audrey, Torok-Castanza, Joanne, Prockop, Susan E., Scaradavou, Andromachi, Curran, Kevin, Spitzer, Barbara, Cancio, Maria, Ruggiero, Julianne, Allen, Jennifer, Harris, Andrew, Oved, Joseph, O'Reilly, Richard J., and Boelens, Jaap Jan

Published
2024
Full Text
View/download PDF

13. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC

Author

Cuvelier, Geoffrey D.E., Logan, Brent R., Prockop, Susan E., Buckley, Rebecca H., Kuo, Caroline Y., Griffith, Linda M., Liu, Xuerong, Yip, Alison, Hershfield, Michael S., Ayoub, Paul G., Moore, Theodore B., Dorsey, Morna J., O'Reilly, Richard J., Kapoor, Neena, Pai, Sung-Yun, Kapadia, Malika, Ebens, Christen L., Forbes Satter, Lisa R., Burroughs, Lauri M., Petrovic, Aleksandra, Chellapandian, Deepak, Heimall, Jennifer, Shyr, David C., Rayes, Ahmad, Bednarski, Jeffrey J., Chandra, Sharat, Chandrakasan, Shanmuganathan, Gillio, Alfred P., Madden, Lisa, Quigg, Troy C., Caywood, Emi H., Dávila Saldaña, Blachy J., DeSantes, Kenneth, Eissa, Hesham, Goldman, Frederick D., Rozmus, Jacob, Shah, Ami J., Vander Lugt, Mark T., Thakar, Monica S., Parrott, Roberta E., Martinez, Caridad, Leiding, Jennifer W., Torgerson, Troy R., Pulsipher, Michael A., Notarangelo, Luigi D., Cowan, Morton J., Dvorak, Christopher C., Haddad, Elie, Puck, Jennifer M., and Kohn, Donald B.

Published
2022
Full Text
View/download PDF

14. 89Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia.

Author

Herrero Alvarez, Natalia, Molvi, Zaki, Lupo, Kyle, Urraca, Jessica, Balderes, Paul, Nyakatura, Elisabeth K., Khan, Abdul G., Viray, Tara, Lewis, Jason S., and O'Reilly, Richard J.

Subjects
ACUTE myeloid leukemia, HEMATOPOIETIC stem cell transplantation, CHIMERIC proteins, KILLER cells, LEUKEMIA, T cells
Abstract

Purpose: Immune cells are capable of eliminating leukemic cells, as evidenced by outcomes in hematopoietic cell transplantation (HCT). However, patients who fail induction therapy will not benefit from HCT due to their minimal residual disease (MRD) status. Thus, we aimed to develop an immunomodulatory agent to reduce MRD by activating immune effector cells in the presence of leukaemia cells via a novel fusion protein that chimerises two clinically tolerated biologics: a CD33 antibody and the IL15Ra/IL15 complex (CD33xIL15). Methods: We generated a set of CD33xIL15 fusion protein constructs with varying configurations and identified those with the best in vitro AML-binding, T cell activation, and NK cell potentiation. Using 89Zr-immunoPET imaging we then evaluated the biodistribution and in vivo tumour retention of the most favourable CD33xIL15 constructs in an AML xenograft model. Ex vivo biodistribution studies were used to confirm the pharmacokinetics of the constructs. Results: Two of the generated fusion proteins, CD33xIL15 (N72D) and CD33xIL15wt, demonstrated optimal in vitro behaviour and were further evaluated in vivo. These studies revealed that the CD33xIL15wt candidate was capable of being retained in the tumour for as long as its parental CD33 antibody, Lintuzumab (13.9 ± 3.1%ID/g vs 18.6 ± 1.1%ID/g at 120 h). Conclusion: This work demonstrates that CD33xIL15 fusion proteins are capable of targeting leukemic cells and stimulating local T cells in vitro and of concentrating in the tumour in AML xenografts. It also highlights the importance of 89Zr-immunoPET to guide the development and selection of tumour-targeted antibody-cytokine fusion proteins. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

Author

Shouval, Roni, Fein, Joshua A., Cho, Christina, Avecilla, Scott T., Ruiz, Josel, Tomas, Ana Alarcon, Sanchez-Escamilla, Miriam, Flores, Nerea Castillo, Yáñez, Lucrecia, Barker, Juliet N., Dahi, Parastoo, Giralt, Sergio A., Geyer, Alexander I., Gyurkocza, Boglarka, Jakubowski, Ann A., Lin, Richard J., O'Reilly, Richard J., Papadopoulos, Esperanza B., Politikos, Ioannis, Ponce, Doris M., Sauter, Craig S., Scordo, Michael, Shaffer, Brian, Shah, Gunjan L., Sullivan, James P., Tamari, Roni, van den Brink, Marcel R.M., Young, James W., Nagler, Arnon, Devlin, Sean, Shimoni, Avichai, and Perales, Miguel-Angel

Published
2022
Full Text
View/download PDF

16. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation

Author

Lakkaraja, Madhavi, Scordo, Michael, Mauguen, Audrey, Cho, Christina, Devlin, Sean, Ruiz, Josel D., Klein, Elizabeth, Avecilla, Scott T., Boulad, Farid, Cancio, Maria I., Curran, Kevin J., Jakubowski, Ann A., Kernan, Nancy A., Kung, Andrew L., O'Reilly, Richard J., Papadopoulos, Esperanza B., Prockop, Susan, van Roessel, Ichelle, Scaradavou, Andromachi, Shaffer, Brian C., Shah, Gunjan, Spitzer, Barbara, Tamari, Roni, Giralt, Sergio A., Perales, Miguel-Angel, and Boelens, Jaap Jan

Published
2022
Full Text
View/download PDF

17. Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation

Author

Major-Monfried, Hannah, primary, Hosszu, Kinga, additional, McAvoy, Devin P., additional, Vallone, Alexander, additional, Shukla, Neerav, additional, Gillio, Alfred, additional, Spitzer, Barbara, additional, Kung, Andrew L., additional, Cancio, Maria, additional, Curran, Kevin, additional, Scaradavou, Andromachi, additional, Oved, Joseph H., additional, O'Reilly, Richard J., additional, Boelens, Jaap Jan, additional, and Harris, Andrew C., additional

Published
2024
Full Text
View/download PDF

19. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant

Author

Prockop, Susan E., Hasan, Aisha, Doubrovina, Ekaterina, Dahi, Parastoo B., Rodriguez-Sanchez, Irene, Curry, Michael, Mauguen, Audrey, Papanicolaou, Genovefa A., Su, Yiqi, Yao, JinJuan, Arcila, Maria, Boulad, Farid, Castro- Malaspina, Hugo, Cho, Christina, Curran, Kevin J., Giralt, Sergio, Kernan, Nancy A., Koehne, Guenther, Jakubowski, Ann, Papadopoulos, Esperanza, Perales, Miguel-Angel, Politikos, Ioannis, Price, Keith, Selvakumar, Annamalai, Sauter, Craig S., Tamari, Roni, Vizconde, Teresa, Young, James W., and O'Reilly, Richard J.

Subjects
T cells -- Health aspects, Cellular therapy -- Testing, Viremia -- Care and treatment, Cytomegalovirus infections -- Care and treatment, Hematopoietic stem cells -- Transplantation, Health care industry
Abstract

BACKGROUND. Refractory CMV viremia and disease are associated with significant morbidity and mortality in recipients of hematopoietic stem cell transplant (HCT). METHODS. In phase I/II trials, we treated 67 subjects for CMV viremia or disease arising after HCT with adoptive transfer of banked, third-party, CMVpp65-sensitized T cells (CMVpp65-VSTs). All were evaluable for toxicity and 59 for response. Evaluable subjects had CMV disease or persisting viremia that had failed at least 2 weeks of induction therapy with a median of 3 antiviral drugs; 84.7% had more than 3 of 11 high-risk features. CMVpp65-VSTs were specific for 1 to 3 CMVpp65 epitopes, presented by a limited set of HLA class I or II alleles, and were selected based on high-resolution HLA matching at 2 of 10 HLA alleles and matching for subject and subject's HCT donor for 1 or more alleles through which the CMVpp65- VSTs were restricted. RESULTS. T cell infusions were well tolerated. Of 59 subjects evaluable for response, 38 (64%) achieved complete or durable partial responses. CONCLUSIONS. Recipients responding to CMVpp65VSTs experienced an improved overall survival. Of the risk factors evaluated, transplant type, recipient [CD4.sup.+] and [CD8.sup.+] T cell levels prior to adoptive therapy, and the HLA restriction of CMVpp65-VSTs infused each significantly affected responses. In addition, CMVpp65-specific T cells of HCT donor or recipient origin contributed to the durability of both complete and partial responses. TRIAL REGISTRATION. NCT00674648; NCT01646645; NCT02136797 (NIH). FUNDING. NIH (P01 CA23766, R21 CA162002 and P30 CA008748); Aubrey Fund; Claire Tow Foundation; Major Family Foundation; 'Rick' Eisemann Pediatric Research Fund; Banbury Foundation; Edith Robertson Foundation; Larry Smead Foundation., Introduction Cytomegalovirus (CMV) infections remain a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplants (HCTs) (1-5). Although prophylactic or preemptive treatment with ganciclovir and/or foscarnet and, [...]

Published
2023
Full Text
View/download PDF

21. Management of a major varicella zoster exposure in a pediatric oncology population.

Author

Rossetto, Carol, Sepkowitz, Kent, Ackerman, Jill, Corke, Rachel, Pickett, Nina J., Cudjoe, Wini, Eagan, Janet, Kamboj, Mini, O'Reilly, Richard J., and Boulad, Farid

Subjects
CHICKENPOX vaccines, CANCER patients, PEDIATRIC oncology, VACCINATION status, CHILDHOOD cancer
Abstract

Management of the exposure of pediatric oncology patients to varicella zoster virus (VZV) is controversial. We report the exposure of 56 patients to a single child with chicken pox at a pediatric cancer housing facility and describe our strategic approach for their management. We reviewed the immune and clinical status of 56 children with cancer receiving ongoing treatment at Memorial Sloan Kettering Cancer Center (MSK) who, while living at a pediatric cancer housing facility, were exposed to the index patient. The management of patients exposed included: (1) determination of immune status, (2) availability of vaccination history or VZV disease prophylaxis, (3) exposure status and subsequent isolation during the period of incubation, and (4) VZV disease prophylaxis. In addition to the 56 patients exposed to the index case, eight children with cancer treated at other facilities and 11 healthy siblings living in the facility were exposed. Of the 56 MSK patients, 21 were classified as immunosuppressed and received varicella zoster immune globulin (human), intravenous standard immune globulin, or acyclovir based on serostatus and immune function. The cohort was followed for 4 weeks after the exposure and no secondary infections were diagnosed. We performed a risk assessment and created a management plan to control and prevent further exposure and development of disease. No secondary cases developed. This strategic approach could serve as a model for the management of VZV exposure for other pediatric oncology centers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Outcomes Following Matched Sibling Donor Transplant for Severe Combined Immunodeficiency: A Report from the Pidtc

Author

Rayes, Ahmad, primary, Logan, Brent, additional, Liu, Xuerong, additional, Dara, Jasmeen, additional, Buckley, Rebecca H., additional, Oved, Joseph H., additional, Kapoor, Neena, additional, Kapadia, Malika, additional, Chandra, Sharat, additional, Martinez, Caridad, additional, Bunin, Nancy J., additional, Chandrakasan, Shanmuganathan, additional, Burroughs, Lauri M., additional, Bednarski, Jeffrey J, additional, Haines, Hilary, additional, Cuvelier, Geoff D.E., additional, Eissa, Hesham, additional, Talano, Julie A, additional, Saldana, Blachy J, additional, Ebens, Christen L., additional, Chaudhury, Sonali, additional, Shereck, Evan, additional, Aquino, Victor, additional, Knutsen, Alan P., additional, Alexander, Jessie L, additional, Gillio, Alfred P., additional, Chellapandian, Deepak, additional, Shah, Ami J., additional, Miller, Holly K., additional, Lugt, Mark T. Vander, additional, DeSantes, Kenneth, additional, Dorsey, Morna, additional, Parrott, Roberta E, additional, O'Reilly, Richard J., additional, Aguayo-Hiraldo, Paibel, additional, Torgerson, Troy, additional, Leiding, Jennifer W., additional, Marsh, Rebecca A., additional, Griffith, Linda M., additional, Pulsipher, Mike A., additional, Kohn, Donald B., additional, Notarangelo, Luigi D., additional, Cowan, Morton J., additional, Puck, Jennifer, additional, Heimall, Jennifer R., additional, Haddad, Elie, additional, Pai, Sung-Yun, additional, and Dvorak, Christopher C., additional

Published
2024
Full Text
View/download PDF

23. Early CD4 and B Cell Immune Reconstitution As Predictors of Outcomes in T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

Author

Lucas, Alexandre G. Troullioud, primary, Scordo, Michael, additional, Lakkaraja, Madhavi, additional, Cho, Christina, additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Tamari, Roni, additional, Curran, Kevin J., additional, O'Reilly, Richard J., additional, Scaradavou, Andromachi, additional, Gyurkocza, Boglarka, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, and Boelens, Jaap Jan, additional

Published
2024
Full Text
View/download PDF

24. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study

Author

Eissa, Hesham, primary, Thakar, Monica S., additional, Shah, Ami J., additional, Logan, Brent R., additional, Griffith, Linda M., additional, Dong, Huaying, additional, Parrott, Roberta E., additional, O’Reilly, Richard J., additional, Dara, Jasmeen, additional, Kapoor, Neena, additional, Forbes Satter, Lisa, additional, Chandra, Sharat, additional, Kapadia, Malika, additional, Chandrakasan, Shanmuganathan, additional, Knutsen, Alan, additional, Jyonouchi, Soma C., additional, Molinari, Lyndsay, additional, Rayes, Ahmad, additional, Ebens, Christen L., additional, Teira, Pierre, additional, Dávila Saldaña, Blachy J., additional, Burroughs, Lauri M., additional, Chaudhury, Sonali, additional, Chellapandian, Deepak, additional, Gillio, Alfred P., additional, Goldman, Fredrick, additional, Malech, Harry L., additional, DeSantes, Kenneth, additional, Cuvelier, Geoff D.E., additional, Rozmus, Jacob, additional, Quinones, Ralph, additional, Yu, Lolie C., additional, Broglie, Larisa, additional, Aquino, Victor, additional, Shereck, Evan, additional, Moore, Theodore B., additional, Vander Lugt, Mark T., additional, Mousallem, Talal I., additional, Oved, Joeseph H., additional, Dorsey, Morna, additional, Abdel-Azim, Hisham, additional, Martinez, Caridad, additional, Bleesing, Jacob H., additional, Prockop, Susan, additional, Kohn, Donald B., additional, Bednarski, Jeffrey J., additional, Leiding, Jennifer, additional, Marsh, Rebecca A., additional, Torgerson, Troy, additional, Notarangelo, Luigi D., additional, Pai, Sung-Yun, additional, Pulsipher, Michael A., additional, Puck, Jennifer M., additional, Dvorak, Christopher C., additional, Haddad, Elie, additional, Buckley, Rebecca H., additional, Cowan, Morton J., additional, and Heimall, Jennifer, additional

Published
2023
Full Text
View/download PDF

26. T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML

Author

Satty, Alexandra M., primary, Klein, Elizabeth, additional, Mauguen, Audrey, additional, Kunvarjee, Binni, additional, Boelens, Jaap Jan, additional, Cancio, Maria, additional, Curran, Kevin J., additional, Kernan, Nancy A., additional, Prockop, Susan E., additional, Scaradavou, Andromachi, additional, Spitzer, Barbara, additional, Tamari, Roni, additional, Ruggiero, Julianne, additional, Torok-Castanza, Joanne, additional, Mehta, Parinda A., additional, O’Reilly, Richard J., additional, and Boulad, Farid, additional

Published
2023
Full Text
View/download PDF

28. Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations

Author

Kunvarjee, Binni, primary, Bidgoli, Alan, additional, Madan, Rebecca Pellett, additional, Vidal, Esther, additional, McAvoy, Devin, additional, Hosszu, Kinga K., additional, Scaradavou, Andromachi, additional, Spitzer, Barbara G., additional, Curran, Kevin J., additional, Cancio, Maria, additional, Harris, Andrew C., additional, O’Reilly, Richard J., additional, Kung, Andrew L., additional, Prockop, Susan, additional, Boelens, Jaap Jan, additional, and Oved, Joseph H., additional

Published
2023
Full Text
View/download PDF

29. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.

Author

O'Reilly, Richard J., Prockop, Susan, and Oved, Joseph H.

Subjects
EPSTEIN-Barr virus diseases, LYMPHOPROLIFERATIVE disorders, T cells, TRANSPLANTATION of organs, tissues, etc., RITUXIMAB, BK virus
Abstract

EBV+ lymphomas constitute a significant cause of morbidity and mortality in recipients of allogeneic hematopoietic cell (HCT) and solid organ transplants (SOT). Phase I and II trials have shown that in HCT recipients, adoptive transfer of EBV-specific T-cells from the HCT donor can safely induce durable remissions of EBV+ lymphomas including 70->90% of patients who have failed to respond to treatment with Rituximab. More recently, EBV-specific T-cells generated from allogeneic 3rd party donors have also been shown to induce durable remission of EBV+ lymphomas in Rituximab refractory HCT and SOT recipients. In this review, we compare results of phase I and II trials of 3rd party and donor derived EBVspecific T-cells. We focus on the attributes and limitations of each product in terms of access, safety, responses achieved and durability. The limited data available regarding donor and host factors contributing to T cell persistence is also described. We examine factors contributing to treatment failures and approaches to prevent or salvage relapse. Lastly, we summarize strategies to further improve results for virus-specific immunotherapies for post-transplant EBV lymphomas. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Racial and Ethnic Disparities in Outcomes following Hematopoietic Stem Cell Transplant (HCT) in Patients with Severe Combined Immunodeficiency (SCID)

Author

Winestone, Lena, primary, Logan, Brent R., additional, Liu, Xuerong, additional, Buckley, Rebecca H., additional, O’Reilly, Richard J, additional, Griffith, Linda M., additional, Puck, Jennifer, additional, Dvorak, Christopher C., additional, Cowan, Morton J, additional, and Haddad, Elie, additional

Published
2023
Full Text
View/download PDF

32. Data from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 5 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 4 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 3 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 6 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 1 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 2 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 1 and Table 2 from A Small-Molecule c-Rel Inhibitor Reduces Alloactivation of T Cells without Compromising Antitumor Activity

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Ouk, Samedy, primary, Liou, Hsiou-Chi, primary, Altan-Bonnet, Grégoire, primary, Tsai, Jennifer J., primary, Oyler, Jennifer E., primary, Smith, Odette M., primary, West, Mallory L., primary, Singer, Natalie V., primary, Doubrovina, Ekaterina, primary, Pankov, Dmitry, primary, Undhad, Chandresh V., primary, Murphy, George F., primary, Lezcano, Cecilia, primary, Liu, Chen, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Materials and Methods from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

Author

Veomett, Nicholas, primary, Dao, Tao, primary, Liu, Hong, primary, Xiang, Jingyi, primary, Pankov, Dmitry, primary, Dubrovsky, Leonid, primary, Whitten, Joseph A., primary, Park, Sun-Mi, primary, Korontsvit, Tatyana, primary, Zakhaleva, Victoria, primary, Casey, Emily, primary, Curcio, Michael, primary, Kharas, Michael G., primary, O'Reilly, Richard J., primary, Liu, Cheng, primary, and Scheinberg, David A., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 3 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

Author

Veomett, Nicholas, primary, Dao, Tao, primary, Liu, Hong, primary, Xiang, Jingyi, primary, Pankov, Dmitry, primary, Dubrovsky, Leonid, primary, Whitten, Joseph A., primary, Park, Sun-Mi, primary, Korontsvit, Tatyana, primary, Zakhaleva, Victoria, primary, Casey, Emily, primary, Curcio, Michael, primary, Kharas, Michael G., primary, O'Reilly, Richard J., primary, Liu, Cheng, primary, and Scheinberg, David A., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 1 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

Author

Veomett, Nicholas, primary, Dao, Tao, primary, Liu, Hong, primary, Xiang, Jingyi, primary, Pankov, Dmitry, primary, Dubrovsky, Leonid, primary, Whitten, Joseph A., primary, Park, Sun-Mi, primary, Korontsvit, Tatyana, primary, Zakhaleva, Victoria, primary, Casey, Emily, primary, Curcio, Michael, primary, Kharas, Michael G., primary, O'Reilly, Richard J., primary, Liu, Cheng, primary, and Scheinberg, David A., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 4 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

Author

Veomett, Nicholas, primary, Dao, Tao, primary, Liu, Hong, primary, Xiang, Jingyi, primary, Pankov, Dmitry, primary, Dubrovsky, Leonid, primary, Whitten, Joseph A., primary, Park, Sun-Mi, primary, Korontsvit, Tatyana, primary, Zakhaleva, Victoria, primary, Casey, Emily, primary, Curcio, Michael, primary, Kharas, Michael G., primary, O'Reilly, Richard J., primary, Liu, Cheng, primary, and Scheinberg, David A., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 1 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

Author

Veomett, Nicholas, primary, Dao, Tao, primary, Liu, Hong, primary, Xiang, Jingyi, primary, Pankov, Dmitry, primary, Dubrovsky, Leonid, primary, Whitten, Joseph A., primary, Park, Sun-Mi, primary, Korontsvit, Tatyana, primary, Zakhaleva, Victoria, primary, Casey, Emily, primary, Curcio, Michael, primary, Kharas, Michael G., primary, O'Reilly, Richard J., primary, Liu, Cheng, primary, and Scheinberg, David A., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 2 from Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

Author

Veomett, Nicholas, primary, Dao, Tao, primary, Liu, Hong, primary, Xiang, Jingyi, primary, Pankov, Dmitry, primary, Dubrovsky, Leonid, primary, Whitten, Joseph A., primary, Park, Sun-Mi, primary, Korontsvit, Tatyana, primary, Zakhaleva, Victoria, primary, Casey, Emily, primary, Curcio, Michael, primary, Kharas, Michael G., primary, O'Reilly, Richard J., primary, Liu, Cheng, primary, and Scheinberg, David A., primary

Published
2023
Full Text
View/download PDF

46. Data from Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB–Controlled Oxidative Stress Responses

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Liou, Hsiou-Chi, primary, Doubrovina, Ekaterina, primary, Derenzini, Enrico, primary, Ouk, Samedy, primary, Tsai, Jennifer J., primary, Smith, Odette M., primary, Levy, Emily R., primary, Kreines, Fabiana M., primary, Ziegler, Carly G.K., primary, Scallion, Mary I., primary, Doubrovin, Mikhail, primary, Heller, Glenn, primary, Younes, Anas, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 5 from Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB–Controlled Oxidative Stress Responses

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Liou, Hsiou-Chi, primary, Doubrovina, Ekaterina, primary, Derenzini, Enrico, primary, Ouk, Samedy, primary, Tsai, Jennifer J., primary, Smith, Odette M., primary, Levy, Emily R., primary, Kreines, Fabiana M., primary, Ziegler, Carly G.K., primary, Scallion, Mary I., primary, Doubrovin, Mikhail, primary, Heller, Glenn, primary, Younes, Anas, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 2 from Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB–Controlled Oxidative Stress Responses

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Liou, Hsiou-Chi, primary, Doubrovina, Ekaterina, primary, Derenzini, Enrico, primary, Ouk, Samedy, primary, Tsai, Jennifer J., primary, Smith, Odette M., primary, Levy, Emily R., primary, Kreines, Fabiana M., primary, Ziegler, Carly G.K., primary, Scallion, Mary I., primary, Doubrovin, Mikhail, primary, Heller, Glenn, primary, Younes, Anas, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 11 from Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB–Controlled Oxidative Stress Responses

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Liou, Hsiou-Chi, primary, Doubrovina, Ekaterina, primary, Derenzini, Enrico, primary, Ouk, Samedy, primary, Tsai, Jennifer J., primary, Smith, Odette M., primary, Levy, Emily R., primary, Kreines, Fabiana M., primary, Ziegler, Carly G.K., primary, Scallion, Mary I., primary, Doubrovin, Mikhail, primary, Heller, Glenn, primary, Younes, Anas, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 9 from Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB–Controlled Oxidative Stress Responses

Author

Shono, Yusuke, primary, Tuckett, Andrea Z., primary, Liou, Hsiou-Chi, primary, Doubrovina, Ekaterina, primary, Derenzini, Enrico, primary, Ouk, Samedy, primary, Tsai, Jennifer J., primary, Smith, Odette M., primary, Levy, Emily R., primary, Kreines, Fabiana M., primary, Ziegler, Carly G.K., primary, Scallion, Mary I., primary, Doubrovin, Mikhail, primary, Heller, Glenn, primary, Younes, Anas, primary, O'Reilly, Richard J., primary, van den Brink, Marcel R.M., primary, and Zakrzewski, Johannes L., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results